A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of PRX003 Administered by Intravenous Infusion in Subjects With Psoriasis
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2017
At a glance
- Drugs PRX 003 (Primary)
- Indications Psoriasis
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Sponsors Prothena
- 28 Sep 2017 Results presented in a Prothena Media Release.
- 08 Aug 2017 According to a Prothena media release, top-line results from this trial are expected in October 2017.
- 05 Jul 2016 According to Prothena Corporation media release, interim data expected by mid-2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History